Undisclosed novel protein driving peripheral liver-brain signaling

The undisclosed novel protein driving peripheral liver-brain signaling is a therapeutic target identified for the treatment of obesity and metabolic disorders (Fierce Biotech, 2024). Discovered by EraCal Therapeutics using a phenotypic screening platform in zebrafish, this protein facilitates a communication pathway between the liver and the brain that regulates appetite and nutrient sensing (FirstWord Pharma, 2024). Unlike the mechanism of GLP-1 receptor agonists, which primarily rely on the vagus nerve to transmit satiety signals, this protein operates through a distinct peripheral axis (PharmaBoardroom, 2024). This independence from the vagal pathway suggests that modulators of this target can act synergistically with existing incretin-based therapies (BioSpace, 2024). The lead small molecule candidate targeting this protein, Era-379, is an oral agent designed to suppress appetite and reduce body weight (Stifel, 2025). In 2024, Novo Nordisk acquired the rights to this program, positioning it as a potential next-generation treatment in the rapidly evolving obesity market (PitchBook, 2024).

Other names

Era-379 targetLiver-brain axis proteinPeripheral appetite-regulating protein

Appetite suppression via a peripheral liver-brain signaling pathway that is independent of the vagus nerve and synergistic with GLP-1 receptor agonists.